Literature DB >> 18480925

Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata.

Juan Jose Vilata1, José A Varela, Luis Olmos, José A Colombo, María A Llorens, Miguel Sainz de los Terreros, Xavier Badía.   

Abstract

The aim of this validation study was to assess the measurement properties of the CECA (Spanish acronym for the Specific Questionnaire for Condylomata Acuminata) in patients with anogenital condylomas. A total of 247 patients aged > 18 years completed the questionnaire on 2 occasions as well as the Dermatology Life Quality Index (DLQI). The CECA questionnaire showed good internal consistency (Cronbach's alpha values of 0.86 and 0.91 in the emotional and sexual activity dimensions) and good testretest reliability (intraclass correlation coefficient 0.76 emotional dimension, 0.82 sexual activity dimension). Patients with de novo lesions and those with more extensive lesions and larger number of warts showed poorer health-related quality of life. CECA and DLQI scores correlated moderately. Patients whose lesions cleared at follow-up or with a reduction of >or= 50% showed a better improvement of health-related quality of life. The CECA questionnaire is a valid, reliable and sensitive tool for the assessment of health-related quality of life in patients with anogenital warts.

Entities:  

Mesh:

Year:  2008        PMID: 18480925     DOI: 10.2340/00015555-0422

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  8 in total

Review 1.  Economic and humanistic burden of external genital warts.

Authors:  Adam J N Raymakers; Mohsen Sadatsafavi; Fawziah Marra; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

2.  The psychosocial burden of anogenital warts on Syrian patients: study of quality of life.

Authors:  Joud Haddad; Fouz Hasan; Abdel Halim Roumeih; Abdullah Omar
Journal:  Heliyon       Date:  2022-06-30

3.  Cross-sectional study estimating the psychosocial impact of genital warts and other anogenital diseases in South Korea.

Authors:  Taek Sang Lee; Smita Kothari-Talwar; Puneet K Singhal; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne M Garland; Woong Ju
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

4.  Development and psychometric properties of the human papillomavirus-quality of life (HPV-QoL) questionnaire to assess the impact of HPV on women health-related-quality-of-life.

Authors:  Pluvio J Coronado; Carmen González-Granados; Mar Ramírez-Mena; Javier Calvo; María Fasero; Mónica Bellón; Javier F García-Santos; Javier Rejas-Gutiérrez
Journal:  Arch Gynecol Obstet       Date:  2022-05-13       Impact factor: 2.493

5.  Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK.

Authors:  Géraldine Dominiak-Felden; Catherine Cohet; Samantha Atrux-Tallau; Hélène Gilet; Amanda Tristram; Alison Fiander
Journal:  BMC Public Health       Date:  2013-11-12       Impact factor: 3.295

6.  HPV-associated anal lesions in HIV+ patients: long-term results regarding quality of life.

Authors:  Paul Wesselmann; Carolynne Schwarze-Zander; Christoph Boesecke; Jürgen Rockstroh; B Stoffels; Tim O Vilz; Tim R Glowka; J C Kalff; Martin W von Websky
Journal:  Int J Colorectal Dis       Date:  2020-03-26       Impact factor: 2.571

7.  Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study.

Authors:  Lani Buenconsejo; Smita Kothari-Talwar; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne Garland
Journal:  Infect Agent Cancer       Date:  2019-10-07       Impact factor: 2.965

8.  Aspects of Langerhans cells and TNF-α in the cutaneous immunity of anogenital warts.

Authors:  John Verrinder Veasey; Adriana Bittencourt Campaner; Rute Facchini Lellis
Journal:  An Bras Dermatol       Date:  2020-02-12       Impact factor: 1.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.